CMHC
Cardiometabolic Health Congress

GREAT DEBATES
in Cardiometabolic Medicine

APRIL 8-10, 2022 | SCOTTSDALE, AZ

CMHC SPRING 2022
CONFERENCE GUIDE

TABLE OF CONTENTS

Welcome Letter	3
Hours of Operation	4
Schedule-at-a-Glance	8 - 12
Expert Speaker Line-Up	16 - 17
Spring 2022 CMHC Accreditation	20 - 21
CME Symposia	22 - 31
Association & Media Partners	32 - 33
Professional Medical Education (Non-CME)	33
Exhibitor Listings	34 - 36

CHAIRPERSONS

George L. Bakris, MD

Professor of Medicine
Director, Am Heart Assoc. Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Christie M. Ballantyne, MD

Professor of Medicine
Professor, Molecular and Human Genetics
Professor, Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
Chief of Cardiology
Chief of Cardiovascular Research
Baylor College of Medicine

Robert H. Eckel, MD

Professor of Medicine, Emeritus
University of Colorado Anschutz Medical Campus
Aurora, CO

Anne L. Peters, MD

Professor, Keck School of Medicine, University of Southern California
Director, USC Clinical Diabetes Programs
USC
Los Angeles, CA

SENIOR PLANNING COMMITTEE

Deepak L. Bhatt, MD, MPH

Professor of Medicine
Harvard Medical School
Executive Director
Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Boston, MA

Pamela B. Morris, MD

Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Keith C. Ferdinand, MD, FACC, FAHA

Professor of Medicine
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Tulane University School of Medicine
New Orleans, LA

Pam R. Taub, MD, FACC, FASPC

Professor of Medicine
Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center
UC San Diego
San Diego, CA

Clyde W. Yancy, MD, MSc

Magerstadt Professor of Medicine
Professor of Medical Social Sciences
Chief, Div. of Cardiology, Northwestern Univ. Feinberg School of Medicine
Assoc. Director, Bluhm Cardiovascular Institute
Northwestern Memorial Hospital
Chicago, IL

WELCOME
TO CMHC SPRING 2022

Valued Colleagues,

Welcome to the beautiful Westin Kierland Resort & Spa for another exciting gathering of the most influential minds in cardiometabolic health. We are pleased to be back in Arizona for the Spring 2022 Cardiometabolic Health Congress (CMHC): Great Debates in Cardiometabolic Medicine. We have been busy making sure this weekend is a relaxing yet enlightening experience for our faculty presenters and provider audience – we can't wait to commence!

The Spring 2022 CMHC conference agenda has been designed by our distinguished Cardiometabolic Health Congress (CMHC) Planning Committee with careful attention to the newest developments in cardiometabolic medicine, while being mindful of the medical and global communities at large. We recognize that the second year of the COVID-19 pandemic has revealed not just the fragilities and disparities in our health care industry, but also some of the resiliencies. Always looking forward to a day when cardiometabolic health will be wholly realized and embraced by multidisciplinary practitioners everywhere, CMHC is focusing the 2022 congress on both facing the disparities and celebrating the resiliencies.

This three-day agenda will expose learners to clinical concepts and strategies designed to inspire a synergistic and comprehensive approach to cardiometabolic health. Since we last met, there have been exciting developments, including in the treatment of heart failure, obesity, lipid management, and progress in many other therapeutic areas we can't wait to delve into with our devoted faculty at the helm.

We hope you enjoy your stay in Scottsdale, time spent with valued colleagues, and most of all the critical cardiometabolic insights you'll bring home. Our loyal and committed attendees are our greatest asset – please accept our sincere thanks for being the momentum that keeps pushing the cardiometabolic health movement forward. We appreciate your steadfast support and hope to see you later this month in Hollywood, FL for Connecting the Dots in Cardiometabolic Medicine, or in Boston, MA for the 17th Annual CMHC on October 19 - 22, 2022.

Yours in Continued Good Health,
The CMHC Team

HOURS OF OPERATION

REGISTRATION HOURS

APRIL 7	APRIL 8	APRIL 9	APRIL 10
THURSDAY	FRIDAY	SATURDAY	SUNDAY
4:00 pm - 6:00 pm	6:30 am - 5:00 pm	7:00 am - 4:00 pm	7:00 am - 11:30 am

MEETING Wi-Fi ACCESS

NETWORK:
CMHC SPRING

PASSWORD:
Lokelma1

SPONSORED BY
AstraZeneca

BREAK AND EXHIBIT HOURS

FRIDAY, APRIL 8, 2022

- 11:45 am – 12:15 pm (Morning Break & Exhibits)
- 1:15 pm – 1:45pm (Break & Exhibits)
- 3:45 pm – 4:00 pm (Afternoon Break & Exhibits)
- 5:30 pm – 6:30 pm (Opening Reception)

SATURDAY, APRIL 9, 2022

- 10:35 am – 11:05 am (Morning Break & Exhibits)
- 12:10 pm – 12:25 pm (Mini-Break)
- 1:25 pm – 1:40 pm (Mini-Break)
- 2:45 pm – 3:15 pm (Afternoon Break & Exhibits)
- 5:00 pm – 6:00 pm (Happy Hour & Giveaways)

SUNDAY, APRIL 10, 2022

- 10:05 am – 10:20 am (Mini-Break)

WELCOME RECEPTION

Friday, April 8
5:30 PM – 6:30 PM

HAPPY HOUR & GIVEAWAYS

Saturday, April 9
5:00 PM – 6:00 PM

Passport to Prizes

1ST PRIZE
TUMI - Small Compact 4 Wheeled Brief

2ND PRIZE
Apple Watch

3RD PRIZE
AirPods

4TH PRIZE
17th Annual Cardiometabolic Health Congress Pass

SATURDAY APRIL 9

5:00 PM – 6:00 PM

EXHIBIT HALL **The prize drawing will take place at 5:45 pm.**

HOW THE GAME WORKS

As an attendee, you will receive a passport book with your registration materials onsite at the conference. To play:

1
Visit each booth listed on the passport.

2
Speak and engage with the exhibitor; take some time to view and learn from their demonstrations.

3
Receive a sticker from the exhibitor to add to their corresponding square on your passport.

4
Once you have filled ALL the squares on your passport, return your completed game card to the CMHC registration table and you will be qualified to participate in the Grand Prize Drawing.

Attendees must be present to qualify for the prize drawings.

THANK YOU SPONSORS

SCHEDULE AT A GLANCE

FRIDAY, APRIL 8, 2022

7:00 AM – 8:30 AM	**CME Breakfast Symposium (Non-CME)** Bridging the Frontiers of Care in Patients with Type 2 Diabetes and Chronic Kidney Disease: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal Outcomes George L. Bakris, MD (Chair) Rajiv Agarwal, MD Katherine R. Tuttle, MD *Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.*
Opening Remarks & SESSION I: CARDIO-RENAL	
8:30 AM	Chair Introduction George L. Bakris, MD
8:30 AM – 9:15 AM	Outcomes Trials in Chronic Kidney Disease I. Improving Renal Outcomes with SGLT-2 Inhibitors and GLP-1 RAs: Data, Interpretations, and Future Outlook Katherine R. Tuttle, MD II. Challenging CKD Case & Expert Panel Discussion Katherine R. Tuttle, MD; Rajiv Agarwal, MD; George L. Bakris, MD
9:15 AM – 9:30 AM	Mini-break
9:30 AM – 11:00 AM	Outcomes Trials in Heart Failure I. SGLT-2is and ARNI Across the HF Spectrum Alanna A. Morris, MD II. New and Emerging Treatment Targets in Heart Failure Ileana L Piña, MD III. ATTR-CM in African Americans: Advances in Diagnosis and Treatment to Help Reduce Disparities and Improve Outcomes *This session is supported in part by Alnylam Pharmaceuticals, Inc.* Keith C. Ferdinand, MD IV. HF Challenging Case & Expert Panel Discussion Keith C. Ferdinand, MD; Alanna A. Morris, MD; Ileana L. Piña, MD; George L. Bakris, MD
11:00 AM – 11:45 AM	Emerging Developments in Hypertension I. Emerging Treatments for Hypertension Keith C. Ferdinand, MD II. Resistant Hypertension: Old and New Debbie Cohen, MD III. Expert Panel Discussion & Audience Q & A Keith C. Ferdinand, MD; Debbie Cohen, MD; George L. Bakris, MD
11:45 AM – 12:15 PM	Morning Break & Exhibits

FRIDAY, APRIL 8, 2022

12:15 PM – 1:15 PM	**PME Lunch Symposium** A Treatment Option for Patients With HFrEF Following a Worsening HF Event Matthew J. Budoff, MD *Sponsored by Merck Sharp and Dohme Corp.*
1:15 PM – 1:45 PM	Break & Exhibits
1:45 PM – 2:30 PM	**Keynote Address** Cardiometabolic Centers of Excellence – a Novel Care Delivery Model to Improve Quality and Outcomes in Cardiometabolic Disease Mikhail N. Kosiborod, MD

SESSION II: DIABETES MANAGEMENT

2:30 PM	Chair Introduction Anne L. Peters, MD
2:30 PM – 2:50 PM	Prediabetes: Screening, Diagnosis, and Management Leigh Perreault, MD
2:50 PM – 3:25 PM	Continuous Glucose Monitoring: Going Beyond HbA1c to Optimize and Individualize the Management of Type 2 Diabetes Viral Shah, MD *This session is supported by Abbott Diabetes.*
3:25 PM – 3:45 PM	Dual GLP-1/GIP Agonists: Are They the Next Big Thing in Diabetes Treatment? Athena Philis-Tsimikas, MD
3:45 PM – 4:00 PM	Afternoon Break & Exhibits
4:00 PM – 4:20 PM	How Can We Converge the Glucocentric and Cardio-Renal Risk Management in Diabetes Patients? Lawrence A. Leiter, MD
4:20 PM – 4:40 PM	The Evolution of Insulin: A 2022 Update Grazia Aleppo, MD, FACE, FACP
4:40 PM – 5:00 PM	Technology in Diabetes Beyond CGM Steven J. Russell MD, PhD
5:00 PM – 5:30 PM	Expert Panel Discussion & Audience Q & A Moderator: Anne L. Peters, MD Panelists: Viral Shah, MD; Athena Philis-Tsimikas, MD; Lawrence A. Leiter MD; Grazia Aleppo, MD, FACE, FACP; Steven J. Russell MD, PhD
5:30 PM – 5:30 PM	Closing Remarks Anne L. Peters, MD
5:30 PM – 6:30 PM	Opening Reception

SCHEDULE AT A GLANCE

SATURDAY, APRIL 9, 2022

7:30 AM – 8:30 AM	**CME Breakfast Symposium** The Evolving Landscape of LDL-C Reduction in High-Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk Christie M. Ballantyne, MD (Chair) Erin D. Michos, MD Robert S. Rosenson, MD Nihar R. Desai, MD *Supported by an educational grant from Novartis Pharmaceuticals Corporation.*

SESSION III: OBESITY AND LIFESTYLE MEDICINE

8:30 AM – 8:35 AM	Chair Introduction and Opening Remarks Robert H. Eckel, MD
8:35 AM – 9:35 AM	Lifestyle Approaches to Target Obesity & Cardiometabolic Risk I. Physical Activity John Jakicic, PhD II. Nutrition and Cardiometabolic Risk Maya Vadiveloo, PhD, RD III. Motivational Interviewing and Behavioral Strategies to Address Weight Management Holly R. Wyatt, MD
9:35 AM – 9:55 AM	The Evolving Landscape of NAFLD and NASH Kenneth Cusi, MD
9:55 AM – 10:35 AM	To Be Resolved: Which Approach is Better for Weight Loss? I. Medical Management Holly R. Wyatt, MD II. Metabolic Surgery Donna H. Ryan, MD III. Clinical Implications: Expert Discussions & Audience Q/A Donna H. Ryan, MD; Holly R. Wyatt, MD; Robert H. Eckel, MD
10:35 AM – 11:05 AM	Morning Break & Exhibits
11:05 AM – 11:25 AM	Addressing Bias, Stigma & Racial Disparities in Obesity Care Fatima C. Stanford, MD
11:25 AM – 12:05 PM	Challenging Cases & Expert Panel Discussion and Q&A Moderator: Robert H. Eckel, MD Panelists: John Jakicic, PhD; Maya Vadiveloo, PhD, RD; Holly R. Wyatt, MD; Fatima C. Stanford, MD; Donna H. Ryan, MD
12:05 PM – 12:10 PM	Closing Remarks Robert H. Eckel, MD

SATURDAY, APRIL 9, 2022

12:10 PM – 12:25 PM	Mini-break
12:25 PM – 1:25 PM	**CME Lunch Symposium** Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, 'High-Intensity Lipid Lowering Therapy' to Improve Outcomes Christie M. Ballantyne, MD (Chair) Pam R. Taub, MD Salim S. Virani, MD *This activity is supported by educational funding provided by Amgen.*
1:25 PM – 1:40 PM	Mini-break

SESSION IV: DYSLIPIDEMIA/ATHEROSCLEROSIS/THROMBOSIS

1:40 PM – 1:45 PM	Chair Introduction Christie M. Ballantyne, MD
1:45 PM – 2:05 PM	ASCVD Risk Assessment and Prevention: Where Do We Stand Now? Salim S. Virani, MD
2:05 PM – 2:25 PM	LDL-C-Lowering Therapies: New Approaches to Address Old Challenges Pam R. Taub, MD, FACC, FASPC
2:25 PM – 2:45 PM	Lp(a) and Cardiovascular Risk Michael J. Wilkinson, MD
2:45 PM – 3:15 PM	Afternoon Break & Exhibits
3:15 PM – 3:35 PM	What's the Scoop with Triglycerides and ASCVD Risk? Karol E. Watson, MD
3:35 PM – 3:55 PM	The Spectrum of Familial Hypercholesterolemia Robert S. Rosenson, MD
3:55 PM – 4:15 PM	Updates in Antithrombotic Therapy for the Cardiometabolic Patient Roxana Mehran, MD
4:15 PM – 5:00 PM	Challenging Cases & Expert Panel Discussion and Q&A Moderator: Christie M. Ballantyne, MD Panelists: Robert H. Eckel, MD; Salim S. Virani, MD; Pam R. Taub, MD, FACC, FASPC; Karol E. Watson, MD; Robert S. Rosenson, MD; Michael J. Wilkinson, MD
5:00 PM	Closing Remarks Christie M. Ballantyne, MD
5:00 PM – 6:00 PM	Happy Hour and Giveaways

SCHEDULE AT A GLANCE

SUNDAY, APRIL 10, 2022

Great Debates in Cardiometabolic Medicine	
7:30 AM – 8:00 AM	Breakfast
8:00 AM – 8:05 AM	Introduction and Opening Remarks Christie M. Ballantyne, MD
8:05 AM – 9:05 AM	Do patients benefit from Omega-3 Fatty Acids for CVD Prevention? I. Yes Michael Miller, MD II. No Karol E. Watson, MD III. Expert Discussions & Audience Q & A Christie M. Ballantyne, MD (Moderator)
9:05 AM – 10:05 AM	What is the Standard of Care for Heart Failure with Preserved Ejection Fraction (HFpEF)? I. SGLT-2 Inhibitors Mikhail N. Kosiborod, MD II. ARNI and Others Alanna A. Morris, MD III. Expert Discusssions & Audience Q & A Ileana L Piña, MD (Moderator)
10:05 AM – 10:20 AM	Mini-break
10:20 AM – 11:20 AM	Drawing The Line Between Primary and Secondary Cardiovascular Prevention: Essential or Too Simplistic? I. Essential Salim S. Virani, MD II. Too Simplistic Pam R. Taub, MD, FACC, FASPC III. Expert Discussions & Audience Q & A Christie Ballantyne, MD (Moderator)
11:20 AM – 12:20 PM	The Plate Debate: Which Approach is Better for the Management of Obesity and Cardiometabolic Risk? I. Plant-based diets Monica Aggarwal, MD II. Low-carb diets David Ludwig, MD III. It's more complex than that Holly R. Wyatt, MD IV. Expert Discussions & Audience Q & A Moderator: Robert H. Eckel, MD
12:20 PM – 12:30 PM	Closing Remarks Christie Ballantyne, MD

CMHC Cardiometabolic Health Congress

EDUCATIONALLY PARTNERED WITH A4M MMI

Connecting the Dots in Cardiometabolic Medicine:

Integrative Approaches to Improve Patient Care

APRIL 29 – 30, 2022

THE DIPLOMAT BEACH RESORT IN HOLLYWOOD, FL

The American Academy of Anti-Aging Medicine (A4M) and Cardiometabolic Health Congress (CMHC) have partnered to deliver **a unique 2-day meeting that will explore the connections between cardiometabolic risk and the spectrum of integrative and evidence-based interventions to improve cardiometabolic health.**

Leveraging the strengths of A4M, a leader in integrative health & wellness, and CMHC, a leader in comprehensive cardiometabolic disease education, this meeting will combine the forward-thinking of integrative medicine approaches with cutting edge advances and clinical trials. Utilizing thought-provoking and interactive discussions, multidisciplinary experts will cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, and kidney disease.

The meeting will be chaired by renowned experts George Bakris, MD and Mark Houston, MD, and will provide ample opportunity for interacting with thought leaders, with the ultimate goal of helping you walk away with practical and comprehensive strategies to improve patient care.

CONFERENCE **CO-CHAIRS**

George L. Bakris
MD

Mark C. Houston,
MD, MS, FACP, ABAARM

CONFERENCE **VENUE**

DIPLOMAT BEACH RESORT HOLLYWOOD,
CURIO COLLECTION BY HILTON

3555 S Ocean Dr,
Hollywood, FL 33019
Phone: (954) 602-6000

REGISTER NOW AND **SAVE $100**

Use code **CMHC100**

www.cardiometabolichealth.org

CMHC
Cardiometabolic Health Congress

All modules are available online

Foundations of Cardiometabolic Health Certification Course

EARN 60+ HOURS OF CREDIT

Certified Cardiometabolic Health Professional (CCHP)

MODULE 1:	Lifestyle Management
MODULE 2:	Obesity Management
MODULE 3:	Type 2 Diabetes
MODULE 4:	Hypertension
MODULE 5:	Lipid Management
MODULE 6:	Cardiovascular Disease COMING MAY 2022!
MODULE 7:	Chronic Kidney Disease
MODULE 8:	Implementing Care Delivery
MODULE 9:	Cardiometabolic Considerations in Racial and Ethnic Minorities

ONSITE SPECIAL

REGISTER TODAY AND SAVE $500 USE CODE **Spring500**

CMHC MASTERCLASS **LIVE**

Women's Cardiometabolic Health and Wellness Retreat

SEPTEMBER 9-11, 2022
Rancho Palos Verdes, CA

This masterclass, led by co-chairs Pam R. Taub, MD and Erin D. Michos, MD will explore the unique challenges in optimizing cardiometabolic health in women across the lifespan. Through interactive and engaging conversations and presentations, experts will address important differences in cardiometabolic risk factors, symptom presentation, prevention and treatment of cardiometabolic diseases in women, as well as important implications for patient care.

More than a conference, this meeting is a true wellness retreat. Hosted in the beautiful Terranea resort on the Southern California coast, it is designed to offer ample opportunities for relaxing and recharging. The agenda for the meeting will be designed to allow you time to explore the resort and the area, and we will incorporate several wellness activities as part of the program. Additionally, there will be plenty of opportunities to interact and learn from the experts in an intimate setting through several networking events. Do not miss the chance to attend this unique retreat and to learn from the experts!

MASTERCLASS **CHAIRS**

PAM R. TAUB
MD, FACC, FASPC

ERIN D MICHOS
MD, MHS, FACC, FAHA, FASE, FASPC

CONFERENCE **VENUE**

TERRANEA RESORT

100 Terranea Way.
Rancho Palos Verdes, CA
90275

REGISTER NOW AND **SAVE $100**

Use code **CMHC100**

DISTINGUISHED FACULTY

Rajiv Agarwal, MD

Professor of Medicine
Indiana University School of Medicine & VA Medical Center
Indianapolis, IN

Monica Aggarwal, MD, FACC

Adjunct Associate Professor, Division of Cardiology
Chief Medical Officer, 4Roots Farm
University of Florida
Orlando, FL

Grazia Aleppo, MD, FACE, FACP

Professor of Medicine
Director, NM Diabetes Training and Education Program
Feinberg School of Medicine
Northwestern University
Chicago, IL

Debbie L. Cohen, MD

Director, Hypertension
Director, Pheochromocytoma/Paraganglioma
Neuroendocrine Tumor Program
Professor of Medicine at the Hospital of the University of Pennsylvania
Philadelphia, PA

Kenneth Cusi, MD, FACP, FACE

Professor of Medicine
Chair, Division of Endocrinology, Diabetes & Metabolism
University of Florida
Gainesville, FL

Nihar R. Desai, MD, MPH

Associate Professor of Medicine
Yale School of Medicine, Section of Cardiovascular Medicine
New Haven, CT

John M. Jakicic, PhD

Professor
University of Kansas Medical Center
Kansas City, MO

Mikhail N. Kosiborod, MD

Co-director, Haverty Cardiometabolic Center of Excellence
VP Research, Saint Luke's Health System
Executive Director, Cardiometabolic Center Alliance, Inc.
Professor of Medicine (Cardiology)- University of Missouri-Kansas City
Kansas City, MO

Lawrence A. Leiter, MD

Professor of Medicine
University of Toronto
Toronto, Canada

David S. Ludwig, MD, PhD

Boston Children's Hospital, Harvard Medical School
Boston, MA

Roxana Mehran, MD

Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes
Director of Interventional Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, NY

Erin D. Michos, MD, MHS

Associate Professor of Medicine (Cardiology) and Epidemiology
Director of Women's Cardiovascular Health
Associate Director of Preventive Cardiology
Johns Hopkins University School of Medicine
Baltimore, MD

Michael Miller, MD, FACC, FAHA

Chief of Medicine, Corporal Michael J Crescenz VAMC, Philadelphia
Vice Chair of Medicine, Hospital of the University of Pennsylvania
Philadelphia, PA

Alanna A. Morris, MD, MSc

Associate Professor of Medicine
Director of Heart Failure Research
Emory University School of Medicine
Atlanta, GA

Leigh Perreault, MD

Associate Professor of Medicine, Epidemiology and Biostatistics
University of Colorado
Aurora, CO

Athena Philis-Tsimikas, MD

Corporate Vice President
Scripps Whittier Diabetes Institute
San Diego, CA

DISTINGUISHED FACULTY

Ileana L. Piña, MD, MPH

Professor of Medicine, Wayne State University
Clinical Professor of Medicine
Central Michigan University
Mount Pleasant, MI

Robert S. Rosenson, MD

Professor of Cardiology and Director of Metabolism and Lipids
Icahn School of Medicine at Mount Sinai
New York, NY

Steven J. Russell, MD, PhD

Associate Professor of Medicine
Massachusetts General Hospital Diabetes Research Center
Boston, MA

Donna H. Ryan, MD

Professor Emerita
Interim Executive Director
Pennington Biomedical Research Center
New Orleans, LA

Viral Shah, MD

Associate Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes
University of Colorado Anschutz Medical Campus
Aurora, CO

Fatima Cody Stanford, MD, MPH, MPA

Obesity Medicine Physician-Scientist
Equity Director, Massachusetts General Hospital Endocrine Division
Director of Diversity, Nutrition Obesity Research Center, Harvard Medical School
Boston, MA

Katherine R. Tuttle, MD

Executive Director for Research, Providence Health Care
Professor of Medicine, University of Washington
Co-Principal Investigator, Institute of Translational Health Sciences, University of Washington/Providence Health & Services
Spokane, WA

Maya Vadiveloo, PhD, RD

Assistant Professor
University of Rhode Island
Kingston, RI

Salim S. Virani, MD, PhD

Associate Professor, Section of Cardiovascular Research
Director, Cardiovascular Disease Fellowship Training Program
Baylor College of Medicine
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center
Investigator, Health Policy, Quality and Informatics Program
Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center for Innovations
Houston, TX

Karol E. Watson, MD, PhD

Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
UCLA
Redondo Beach, CA

Michael Wilkinson, MD, FACC

Assistant Professor
Division of Cardiovascular Medicine
UC San Diego
San Diego, CA

Holly R. Wyatt, MD

Professor
University of Alabama Birmingham
Birmingham, AL

REMEMBERING

Dr. Sarah Hallberg

As you may know, CMHC faculty member Dr. Sarah Hallberg passed away on March 28, 2022. She was scheduled to be here this weekend to deliver what would have been an enlightening session on her topic of expertise: the effect of low-carb diets on insulin resistance, obesity, and type 2 diabetes.

Dr. Sarah, as she was lovingly called by her patients, was an internationally recognized leader in the nutritional management of type 2 diabetes and other obesity-related diseases. The Tedx talk she delivered at Purdue University in 2015 on this topic has been viewed more than 8 million times, is used widely by physicians to educate their diabetic patients about their diet, and has inspired thousands to modify their lifestyles, ultimately reducing or even eliminating their need for medications.

Dr. Hallberg's constant push to challenge the status quo and advocate for evidence-based health guidelines was one of the reasons she was admired by her colleagues and adored by her patients.

The entire CMHC team extends our deepest condolences to Brad, her husband of 24 years, and their children Noah, Ava, and Luna.

CMHC
Cardiometabolic Health Congress

The Premier Destination for Cardiometabolic Innovation

THE PRESENT AND FUTURE

OF CARDIOMETABOLIC HEALTH: ADVANCES AND EXPERT PERSPECTIVES

OCTOBER 19-22, 2022 | BOSTON, MA

The Annual Cardiometabolic Health Congress is making its return back to Boston in 2022—and you're invited! Join the foremost leaders in cardiometabolic medicine for an actionable examination on the latest research and updates in the field.

1000+ Attendees

100+ Speakers

50+ Sponsors

CMHC CHAIRPERSONS

George L. Bakris, MD

NEPHROLOGIST

Christie M. Ballantyne, MD

CARDIOLOGIST

Robert H. Eckel, MD

ENDOCRINOLOGIST

Anne L. Peters, MD

ENDOCRINOLOGIST

HOTEL INFORMATION

BOSTON PARK PLAZA

50 Park Plaza, Boston, MA 02116
Rm Rate: $329
Expires: 8-24-22

REGISTER NOW AND SAVE $200

Use coupon code **Annual22**

www.cardiometabolichealth.org/17th-annual-cmhc-2022/

2022 SPRING CMHC
CME INFORMATION

ACTIVITY TITLE
CMHC Spring 2022: Great Debates in Cardiometabolic Medicine

ACTIVITY DATE
April 8-10, 2022 at the The Westin Kierland Resort & Spa, Scottsdale, AZ

EDUCATIONAL GRANT SUPPORT
CMHC Spring 2022: Great Debates in Cardiometabolic Medicine is supported in part by an independent and unrestricted educational grant from Merck Sharp & Dohme Corp.

TARGET AUDIENCE
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

PROGRAM OVERVIEW
The 2022 CMHC Spring meeting will highlight the latest updates in CKD, heart failure, hypertension, type 2 diabetes, dyslipidemia, lifestyle management, obesity, and cardiovascular health, as well as aim to translate this cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardio-renal-metabolic disorders.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

- Discuss the interrelationships among cardiometabolic risk factors and their impact on the development of cardiometabolic diseases
- Review the latest evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease
- Outline strategies aimed at timely screening and prevention of cardiometabolic disease, including assessment of risk factors and biomarkers, and lifestyle modifications
- Select individualized treatment regimens for patients with cardiometabolic disease based on the efficacy and safety of current and new pharmacotherapies, patient comorbidities and preferences in order to optimize outcomes
- Summarize recent evidence for emerging therapies in order to stay current with the most recent updates in the cardiometabolic field

FACULTY
Please refer to the Expert Speaker Line-Up section in the conference guide.

PROGRAM AGENDA
Please refer to the Schedule-at-a-Glance section in the conference guide.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 16.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 16.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 16.25 contact hour(s) (1.625 CEUs) of the Accreditation Council for Pharmacy Education. Please refer to this **link** for a list of Universal Activity Numbers.

This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 16.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found **online here**.

HOW TO REQUEST CE CREDIT

Learners may earn up to a maximum of 19.75 AMA/ACPE/ANCC/CDR credits for attending all General Sessions (earn up to 16.25 hours) and CME Satellite Symposia (earn up to 3.5 hours). For educational symposia support information, including accreditation, please review the CME Symposia section of the conference guide. Upon completing the activity evaluations, your certificates will be emailed to you.

The evaluation links will be accessible on Sunday, April 10. **Visit this information page to access the evaluation links**. Once the links are posted, attendees will be notified via announcements throughout the day. Several email reminders will be sent post-meeting.

Please claim your CE credits by completing the evaluations by Monday, April 25, 2022.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

For questions regarding the evaluation, please contact: cmhc_eval@cardiometabolichealth.org

CME BREAKFAST SYMPOSIUM

FRIDAY, APRIL 8, 2022

7:00 – 8:30 AM

Bridging the Frontiers of Care in Patients with Type 2 Diabetes and Chronic Kidney Disease: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal Outcomes

Chair: George L. Bakris, MD
Presenters: Rajiv Agarwal, MD; Katherine R. Tuttle, MD

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this symposium, experts will discuss these recent advances and their potential application to patient care.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Rajiv Agarwal, MD
Professor of Medicine
Indiana University School of Medicine & VA Medical Center
Indianapolis, IN

Katherine R. Tuttle, MD
Executive Director for Research, Providence Health Care
Professor of Medicine, University of Washington
Co-Principal Investigator, Institute of Translational Health Sciences,
University of Washington/Providence Health & Services
Spokane, WA

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
- Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
- Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
- Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-077-L01-P)
This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CME GENERAL SESSION

FRIDAY, APRIL 8, 2022

10:10 – 10:30 AM

ATTR-CM in African Americans: Advances in Diagnosis and Treatment to Help Reduce Disparities and Improve Outcomes

Presenter: Keith C. Ferdinand, MD

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionally affects African American patients. Low awareness about the disease, and limited therapeutic options are significant barriers to optimal care, however, significant advances have been made in the development of novel targeted-therapeutics that may improve patient outcomes. This session is going to cover some of those advances in order to increase awareness about current gaps and disparities in ATTR-CM.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Tulane University School of Medicine
New Orleans, LA

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Define the pathophysiology, prevalence, and types of ATTR-CM.
- Recognize the disproportionate burden of ATTR-CM in African Americans and the significance of Val122I mutation.
- List current and emerging screening and diagnostic approaches aimed to optimize the early identification of African American patients with ATTR-CM.
- Review the different options for the treatment of ATTR-CM, including new and emerging novel targeted agents.

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Alnylam Pharmaceuticals, Inc.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 0.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-065-L01-P)
This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CME GENERAL SESSION

FRIDAY, APRIL 8, 2022

2:50 – 3:25 PM

Continuous Glucose Monitoring: Going Beyond HbA1c to Optimize and Individualize the Management of Type 2 Diabetes

Presenter: Viral N. Shah, MD

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Measuring HbA1c has been the method of choice to assess glucose control; however, it does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications, as well as overall glycemic variability. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations derived from interstitial fluid; and studies with CGM have demonstrated its efficacy and safety in this setting. This session is going to overview the guidelines for the use of CGM in T2DM, as well as important data and clinical considerations.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Viral Shah, MD
Associate Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes
University of Colorado Anschutz Medical Campus
Aurora, CO

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Summarize the guidelines and evidence for the appropriate use of CGM in patients with type 2 diabetes.
- Explain ambulatory blood glucose profile (AGP) data and other important CGM metrics in patients with type 2 diabetes.
- List new and emerging CGM technologies and their associated clinical features.
- Incorporate the use of CGM when appropriate to individualize therapy in patients with type 2 diabetes.

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Abbott Diabetes.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 0.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-068-L01-P)
This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CME BREAKFAST SYMPOSIUM

SATURDAY, APRIL 9, 2022

7:30 – 8:30 AM

The Evolving Landscape of LDL-C Reduction in High-Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk

Chair: Christie M. Ballantyne, MD
Presenters: Erin D. Michos, MD; Robert S. Rosenson, MD; Nihar R. Desai, MD

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps. During this symposium, experts will discuss the efficacy and safety of these new approaches, how they fit in with the current treatment options for LDL-C lowering, and application to patient care.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Christie M. Ballantyne, MD
Professor of Medicine
Professor, Molecular and Human Genetics
Professor, Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
Chief of Cardiology
Chief of Cardiovascular Research
Baylor College of Medicine
Houston, TX

Erin D. Michos, MD, MHS
Associate Professor of Medicine (Cardiology) and Epidemiology
Director of Women's Cardiovascular Health
Associate Director of Preventive Cardiology
Johns Hopkins University School of Medicine
Baltimore, MD

Robert S. Rosenson, MD
Professor of Cardiology and Director of Metabolism and Lipids
Icahn School of Medicine at Mount Sinai
New York, NY

Nihar R. Desai, MD, MPH
Associate Professor of Medicine
Yale School of Medicine, Section of Cardiovascular Medicine
New Haven, CT

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
- Interpret the data from across major trials and real-world studies with PCSK9 inhibitors and their implications for patient selection
- Review the new approaches with novel LDL-C lowering agents and their potential impact in ASCVD risk reduction
- Select individualized treatment strategies for hypercholesterolemic patients that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-078-L01-P)
This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CME LUNCH SYMPOSIUM

SATURDAY, APRIL 9, 2022

11:25 AM – 12:25 PM

Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, 'High-Intensity Lipid Lowering Therapy' to Improve Outcomes

Chair: Christie M. Ballantyne, MD
Presenters: Salim S. Virani, MD, PhD; Pam R. Taub, MD

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Patients with a recent myocardial infarction (MI) are classified as very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events according to current guidelines, however, targeted LDL-C achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. For example, recent numbers from the GOULD registry, have shown that <40% of patients with a prior MI were on optimal LLT at enrollment, and only 13.2% had lipid therapy intensified.

In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience. Despite the intensive medical management following an MI, risk of a recurrent CV event is substantial and patients with a recent MI have significant loss of productivity the year after the event. Furthermore, this burden is more pronounced in very high-risk patients, including those with a high burden of cardiometabolic comorbidities, compared to patients who are not very-high risk. During this symposium, experts will provide guidance on the clinical application of statin and non-statin therapies in this setting, as well as information about new and emerging studies that can further inform patient selection in order to optimize outcomes.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Christie M. Ballantyne, MD
Professor of Medicine
Professor, Molecular and Human Genetics
Professor, Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
Chief of Cardiology
Chief of Cardiovascular Research
Baylor College of Medicine
Houston, TX

Salim S. Virani, MD, PhD
Associate Professor, Section of Cardiovascular Research
Director, Cardiovascular Disease Fellowship Training Program
Baylor College of Medicine
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center
Investigator, Health Policy, Quality and Informatics Program
Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center for Innovations
Houston, TX

Pam R. Taub, MD, FACC, FASPC
Professor of Medicine
Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center
UC San Diego
San Diego, CA

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
- Interpret the data from across major trials and real-world studies with PCSK9 inhibitors and their implications for patient selection
- Review the new approaches with novel LDL-C lowering agents and their potential impact in ASCVD risk reduction
- Select individualized treatment strategies for hypercholesterolemic patients that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-079-L01-P)
This is a knowledge-based activity.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURES

Information on planner and faculty disclosure is available by following this **link**.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CMHC Cardiometabolic Health Congress

The 2022 Cardiometabolic Health Congress gratefully acknowledges the following

ASSOCIATION PARTNERS

ASPC The American Society for Preventive Cardiology

LDN Research Trust

American Society of Endocrine Physician Assistants ASEPA

OAC Obesity Action Coalition

APAC Academy of Physician Associates in Cardiology

Asian Pacific Society of Cardiology Towards Excellence 1956

DR. STEPHEN SINATRA HeartMD INSTITUTE

GLI Global Liver Institute

National Minority Health Alliance

APPA American Pharmacy Purchasing Alliance

AMWA American Medical Women's Association The Vision and Voice of Women in Medicine since 1915

ADCES Massachusetts Coordinating Body

The Endocrine Society

MCNP Massachusetts Coalition of Nurse Practitioners

ABC Association of Black Cardiologists, Inc. Saving the Hearts and Minds of a Diverse America

Arizona Academy of Family Physicians Strong Medicine for Arizona

TCOYD Taking Control of Your Diabetes

MEDIA PARTNERS

EMJ

BENTHAM SCIENCE

VuMedi

Karger

medical sciences

MED TECH OUTLOOK

Nutrition Today

The European Journal of Cardiovascular Medicine

Healio Cardiology today

Pharmacy Podcast Network

Reviews in Cardiovascular Medicine

MEDIZZY Inspire, Motivate & Educate

PROFESSIONAL MEDICAL EDUCATION (NON-CME)

Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.

PME LUNCH SYMPOSIUM

A Treatment Option for Patients With HFrEF Following a Worsening HF Event

FRIDAY, APRIL 8, 2022
12:15 -1:15 pm | TRAILBLAZERS BALLROOM

Presenter: Matthew Budoff, MD

SPONSORED BY: MERCK

EXHIBITORS

EXHIBIT BREAK HOURS

FRIDAY, APRIL 8, 2022

11:45 am – 12:15 pm	Morning Break & Exhibits
1:15 pm – 1:45pm	Break & Exhibits
3:45 pm – 4:00 pm	Afternoon Break & Exhibits
5:30 pm – 6:30 pm	Opening Reception

SATURDAY, APRIL 9, 2022

10:35 am – 11:05 am	Morning Break & Exhibits
2:45 pm – 3:15 pm	Afternoon Break & Exhibits
5:00 pm – 6:00 pm	Happy Hour & Giveaways

Amgen

1 Amgen Way
Thousand Oaks, California 85383
(602) 334-6831
mancheta@amgen.com
https://www.amgen.com/

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

AstraZeneca

1800 Concord Pike
Wilmington, DE 19803
www.astrazeneca-us.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Bayer Corporation

100 Bayer Boulevard
Whippany, NJ 07981
USA
Phone: +1 862 404 3000
www.bayer.us

We are one of the fastest-growing global pharmaceutical companies in the world. Our aim is to discover and manufacture innovative medicines that will improve human health worldwide by diagnosing, preventing and treating diseases. In this way, we are addressing the growing requirements of patients, physicians, healthcare payers and regulatory agencies.

Calroy Health Sciences

14362 N Frank Lloyd Wright, Suite 1000
Scottsdale, Arizona 85260
(800) 609-6409
support@arterosil.com
http://www.arterosil.com

Calroy is dedicated to developing innovative natural solutions to optimize cardiovascular health.
The endothelium and EGX are gaining recognition in the medical community as essential focuses for vascular health. Calroy created Arterosil, the only glycocalyx-regenerating product patented to stabilize and regress vulnerable plaque*. Arterosil's efficacy has been studied more than any EGX supplement with human, animal, and in vitro studies. Arterosil was the first supplement to address the EGX, and has the longest research history.

CMP Pharma

P.O. Box 147
8026 US Highway 264A
Farmville, North Carolina 27828
(760) 522-5780
joanne.bodnar@cmppharma.com
http://cmppharma.com

At CMP Pharma, we address the critical needs of older and younger patient populations through the development and manufacturing of a portfolio of high value semi-solid and liquid products. Our products include leading high-quality branded and generic prescription products, as well as a variety of non-prescription pharmaceutical products, which we distribute to hospitals, long-term care facilities, and retail channels. We've manufactured high-quality pharmaceutical products at our Farmville, North Carolina facility since 1986.

Corcept Therapeutics

149 Commonwealth Drive
Menlo Park, California 94025
(650) 327-3270
info@corcept.com
http://www.corcept.com

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. The company's first product, Korlym® (mifepristone) 300mg Tablets has been approved by the FDA for the control of hyperglycemia associated with Cushing's syndrome. www.corcept.com

Merck Sharp and Dohme Corp.,

351 N. Sumneytown Pike
North Wales, Pennsylvania 19454
(908) 740-4000
mediarelations@merck.com
https://www.merck.com/

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

CALROY HEALTH SCIENCES | arterosil®

Clinically proven to protect and restore the endothelial glycocalyx

*NEW PATENT! Arterosil stabilizes and regresses vulnerable plaque**

What It Is

Arterosil® is a proprietary dietary supplement formulated with a rare seaweed that contains specialized polysaccharides clinically proven to support arterial and endothelial health.

Who It's For

Arterosil® delivers powerful support to patients with:

- **Cardiovascular Disease**
- **Arterial or Carotid Plaque**
- **Coronary Artery Disease**
- **Erectile Dysfunction**
- **Diabetic Neuropathy**
- **Hyperglycemia**
- **Raynaud's**
- **Angina**
- **Diabetes**
- **Hypertension**
- **Hypercholesterolemia**
- **Peripheral Artery Disease**



How It Works

The special polysaccharides in Arterosil® help rebuild the endothelial glycocalyx—the slippery inner lining of every artery, vein, and capillary in the body. This supports endothelial health, protects and stabilizes plaque, may regress plaque, and enhances NO production.

"The amazing results that I've had in my practice: on average, we're seeing about a **52% reduction in total carotid plaque**, and that's in people that I've been working with for years and have had on every integrative intervention, and most of them with really stubborn and difficult to reverse plaque."

KRISTINE BURKE, MD

U.S. Patent No. 11,135,238

***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.**

© 2022 Calroy Health Sciences, LLC. All rights reserved. *This material is for licensed healthcare providers only.* **arterosil.com**

CMHC
Cardiometabolic Health Congress

GREAT DEBATES
in Cardiometabolic Medicine

APRIL 8-10, 2022 | SCOTTSDALE, AZ

CMHC SPRING 2022
CONFERENCE GUIDE